Objective: Sudden gains (SGs), broadly defined as sudden symptom reductions occurring between two consecutive treatment sessions, have been associated with improved treatment outcomes in anxiety and depression. The present study is the first to formally define SGs in anorexia nervosa and explore the characteristics, demographic and baseline clinical predictors, and clinical impact of SGs in anorexia nervosa.
identify which components of therapy are most important in affecting longer-term symptom change.
One characteristic of the therapeutic process is sudden gains (SGs); defined as sudden reductions in symptoms between two consecutive treatment sessions. SGs were first introduced by Tang and DeRubeis (1999) in the context of cognitive behavioral therapy (CBT) for depression, who argued that SGs should be large (a) in absolute terms, (b) relative to symptom severity before the gain, and (c) relative to symptom fluctuation preceding and following the gain. They defined SGs using scores on the Beck depression inventory (BDI; Beck & Steer, 1987) :
A sudden gain occurred between session N and session N 1 1 if (a) the gain was at least 7 BDI points (BDI N -BDI N11 7); (b) the gain represented at least 25% of the pregain session's BDI score (BDI N -BDI N11 0.25 3 BDI N ), and (c) the mean BDI score of the three therapy sessions before the gain (sessions N -2, N -1, and N) was significantly higher than the mean BDI score of the three therapy sessions after the gain (sessions N 1 1, N 1 2, and N 1 3) using a two-sample t test with a of .05. (Tang & DeRubeis, 1999) Greater than 50% of treatment responders experienced SGs during treatment (Tang & DeRubeis, 1999) and those who experienced SGs were less depressed at post-treatment and 18-month follow-up compared to those who did not.
The original definition has been criticized and altered (Hardy et al., 2005) . The "absolute magnitude" criterion has been criticized for being arbitrary (Hofmann, Schulz, Meuret, Moscovitch, & Suvak, 2006) ; the "relative magnitude" criterion has been criticized for assuming that symptom measures are ratio scales (Utzinger, Goldschmidt, Crosby, Peterson, & Wonderlich, 2016) and has been found to have minimal impact on SG selection (Tang, DeRubeis, Beberman, & Pham, 2005) ; and the "stability" criterion has been criticized for precluding examination of gains between the first and second treatment sessions (Aderka, Nickerson, Bøe, & Hofmann, 2012) . However, despite variations in definitions, SGs have been consistently associated with better treatment outcomes (Aderka et al., 2012) .
The majority of studies on SGs have focused on anxiety and depression. Only one study has assessed the role of SGs in eating disorders, measured using the change in eating disorder symptoms scale (CHEDS; Spangler, 2010) , in CBT for bulimic eating disorders. SGs were defined using two criteria: the "absolute magnitude criterion" required a decrease of at least 12 points on the CHEDS, and the "stability criterion" was based on that originally used by Tang and DeRubeis (1999) . Over 50% of participants had at least one SG, and those experiencing SGs had better CHEDS outcome scores post-treatment (Cavallini & Spangler, 2013) . To date, no study has assessed whether SGs occur in patients with AN during treatment, and, if so, whether these are related to treatment outcomes.
There is also debate regarding the importance of the timing of SGs. Tang and DeRubeis (1999) found that SGs typically occurred early, around session 5, and there is some evidence to suggest that SGs early in treatment are more relevant to treatment outcomes (Lutz, Bachmann, Tschitsaz, Smart, & Lambert, 2007; Stiles et al., 2003) .
However, there is considerable variation in the definition of what constitutes "early". Furthermore, in a large meta-analysis, Aderka et al. (2012) found no significant differences in outcomes between those who experienced SGs early versus later in treatment.
Although SGs have been associated with better outcomes posttreatment, this is not always maintained at longer-term follow-up (Clerkin, Teachman, & Smith-Janik, 2009 ). In addition, SGs are often only associated with improvements in the primary outcome measure, which is typically the same measure used to define SGs (Aderka et al., 2012) .
This may be because of definitions of SGs being too lenient, such that individuals who experience SGs are simply those who improve on the target measure during treatment. Additional criteria may therefore be required in order to ensure that SGs are truly sudden and are measuring more than simply symptom change during treatment.
There has been considerable debate regarding how SGs should be defined and measured in the context of AN (Utzinger et al., 2016) . The current study therefore aimed to operationalize SGs, using data from a clinical trial of AN. We based our criteria on those proposed by Tang and DeRubeis (1999) , adding an additional criterion of "suddenness". We aimed to explore whether there are SGs in body mass index (BMI) during treatment of AN; describe the characteristics of SGs, including their frequency, magnitude, and timing; and determine whether the proportion and timing of SGs predicts outcomes at 6, 12, and 24 months follow-up. We also aimed to determine whether baseline variables (including demographic and clinical characteristics) differed between those who did and did not experience SGs during treatment.
| M E TH OD

| Data source
The current study used data from the Maudsley outpatient study of treatments for AN and related conditions (MOSAIC; Schmidt et al., 2015) , and this trial's 2-year follow-up (Schmidt et al., 2016) ; a large multicenter, two-arm superiority RCT of adult outpatients with broadly defined AN. Patients were randomized to receive one of two treatments: the Maudsley model of AN treatment for adults (MANTRA), an empirically based cognitive-interpersonal manualized treatment targeting factors thought to maintain symptoms of AN (Schmidt & Treasure, 2006; Treasure & Schmidt, 2013) ; or specialist supportive clinical management (SSCM), a manualized treatment, which involves providing information, advice, and encouragement in a supportive therapeutic manner (McIntosh et al., 2006 (Schmidt et al., , 2016 . Exclusion criteria for this study were having fewer than four weight measurements and no height measurement. Information regarding availability of weight data is presented in Figure 1 . As can be seen from Figure 1 , almost 30% of MOSAIC patient files were missing. This is because of factors such as patients failing to start treatment (n 5 10), files being lost, and therapist noncompliance with record keeping, with two therapists accounting for 10 missing files. Comparisons of demographic and clinical characteristics of missing MOSAIC patients and the present subsample are presented in Table 1 , indicating minimal differences between these two subsamples.
| Outcome measures
The primary outcome in the MOSAIC trial was BMI (kg/m 2 ). Other secondary outcome measures included: ED psychopathology, measured using the eating disorders examination (EDE) interview (Fairburn, Cooper, & O'Connor, 2008) , or the questionnaire form of this assessment (EDE-Q); general psychopathology, measured using the depression, anxiety, and stress scale-21 (DASS-21; [Lovibond & Lovibond, 1995] ); obsessive-compulsive symptomatology, measured using the obsessive compulsive inventory-revised (OCI-R; [Foa et al., 2002] ); and psychosocial impairment, measured using the clinical impairment assessment (CIA; Bohn & Fairburn, 2008) . Information regarding reliability and validity of these measures can be found elsewhere (see Schmidt et al., 2015) . EDE and EDE-Q data in the MOSAIC trial were combined into a single EDE outcome measure. BMI and EDE was measured at baseline and 6, 12, and 24 months follow-up. All other outcomes were measured at baseline and 24 months follow-up.
| Procedure
Session-by-session weight measures were extracted from patients' files. Weight measures taken >365 days after baseline (n 5 84) were excluded to ensure that SGs were not measured after the 12-month follow-up. The researchers recorded the session at which each weight measure was taken and the number of days between baseline and each session. All other data (demographic characteristics, clinical details, and outcome measures described above) were extracted from MOSAIC trial databases.
| Defining SGs
Weight measures were transformed into BMI (weight/height) was calculated using the mean height of our sample. Although it may be argued that a weight gain expected to be the norm within the NICE guidelines is not "large", the mean weight gain during treatment for AN is much lower than this recommended amount (Hartmann, Weber, Herpertz, Zeeck, & German Treatment Guideline Group for Anorexia Nervosa, 2011) . Expecting a weight gain of more than this amount may therefore be considered unrealistic. The second criterion of relative magnitude was dropped, as it has been shown to have minimal impact on SG selection (Tang et al., 2005) . Meeting the third criterion of stability required the mean BMI of the three measures taken during sessions N -2, N -1, and N to be significantly lower than the mean BMI of sessions N 1 1, N 1 2, and N 1 3, as calculated using an independent samples t test (a 5 0.05). To maximize data inclusion for SG calculation, when BMI gains occurred between sessions where there were two pregain and/or two postgain measures, t tests were calculated using these values. Finally, we added an additional criterion of "suddenness", which required the rate of BMI increase between sessions N and N 1 1 to be 1.5 times the rate of BMI change between sessions N -1 and N.
Because of considerable variation in the number of weight measures per participant, the proportion of SGs was calculated by dividing patients' total number of SGs by that patients' maximum possible number of SGs (i.e., total number of weight measure-3). because of the effects of these variables on weight, for example because of water retention (Rigaud, Boulier, Tallonneau, Brindisi, & Rozen, 2010) . Finally, although not found to have significant effects on the outcome in the primary trial analyses (Schmidt et al., , 2016 ) treatment effects were also allowed for by adding treatment group into the regression model.
To determine whether the timing of the first SG predicts treatment outcomes, regression analyses were repeated for just those individuals experiencing SGs, with the independent variable: number of days between randomization and the first SG.
| R ESU L TS
| Describing SGs
A total of 1,697 treatment sessions were analyzed for the identification of SGs across all participants, creating 1,607 between-session comparisons. Within our final sample, the median number of weight measurements was 20 (range 5 4-35), and the median length of time between measures was 7 days (range 5 3-140).
There were 327 between-session comparisons meeting the "absolute magnitude" criterion, 122 of which also met the "stability" criterion. Adding the criterion of "suddenness" left 102 SGs amongst 55 participants. Thus, 61.8% of all participants experienced at least one SG in BMI during therapy.
We examined the length, frequency, magnitude, and timing of SGs during both treatments. The median number of days between pregain and postgain weight measures was 7 (range 5 5-49) for both treatments. The median number of SGs experienced by patients in both treatment groups was 1 (MANTRA range 5 0-8; SSCM range 5 0-5). SGs occurred most often after session 12 for MANTA and after sessions 5, 9, or 12 for SSCM (see Figure 2) . Three participants experienced a SG after their first session with a close other (session CO1).
| Characteristics of individuals experiencing SGs
Those who had at least one SG had spent significantly more years in education (median 5 Table 2 , Supporting Information). Table 3 shows the mean BMI and EDE global scores, as measured at baseline and 6, 12, and 24 months postrandomization and all other outcomes measured at baseline and 24 months postrandomization, separately for individuals who did and did not experience SGs.
| Summary statistics of outcome measures
| Associations between the proportion of SGs and long-term treatment outcomes
The proportion of SGs was a significant positive predictor of BMI change between baseline (0 months) and 6, 12, and 24 months postrandomization, with large sizes of effect (Table 4) . Our model did not explain a significant amount of the variance in the change in any other outcome measures.
| Associations between the number of days to a patient's first SG and long-term treatment outcomes
The number of days between randomization and a patient's first SG was a significant negative predictor of BMI change between baseline (0 months) and 6 and 12 months postrandomization, with moderate sizes of effect. However, the number of days between randomization and a patient's first SG was not a significant predictor of BMI change between baseline and 24 months postrandomization (Table 5 ). The number of days between randomization and a patient's first SG was not a significant predictor of change in any of the MOSAIC trial secondary outcomes. It should also be noted that there was not a significant correlation between the proportion of SGs and the number of days to a patient's first SG (p 5 .13).
| D I SCUSSION
This study was the first to define and operationalize SGs in the context of AN. We found that 61.8% of patients experienced at least one SG in BMI during treatment. As hypothesized, a larger proportion of SGs predicted larger increases in BMI between baseline and 6, 12, and 24 months postrandomization. Amongst those experiencing at least one SG during treatment, fewer days between randomization and a patient's first SG predicted a larger increase in BMI between baseline and both 6 and 12 months postrandomization.
Despite including an additional criterion of suddenness, the percentage of patients experiencing SGs in the current study is somewhat larger than the 40-50% that has previously been reported during psychological treatment for anxiety and depression (Aderka et al., 2012) . This may be because of differences in outcome measures used to define SGs. Alternatively; it may be that the criterion of absolute magnitude used in this study is more lenient than previous definitions.
The present study required an average between-session gain of 0.183 kg/m 2 per week. It could be argued that this is not a "large" increase in weight, and therefore does not adhere to the criterion of "large absolute magnitude". However, substantial weight gain does not typically occur over short periods of time, and rapid weight gain can be dangerous, especially in the context of AN (Utzinger et al., 2016) . We therefore adapted the SG criteria in order to use BMI as the outcome variable, ensuring that we were adhering to NICE guidelines and not requiring a weight increase that was dangerous or unrealistic.
Compared to those experiencing no SGs, individuals who experienced at least one SG had spent significantly longer in education, and had a significantly lower DASS-21 total score at baseline. The reasons for the association with education are unclear, however lower depression scores have previously been associated with more favorable treatment outcomes in ED treatment Vall & Wade, 2015) . This study therefore supports these findings, suggesting that lower depressions scores are associated with better treatment outcomes during the outpatient treatment of AN. There were no other significant differences between those who did and did not experience SGs during treatment, suggesting that other demographic and clinical characteristics cannot be used to reliably differentiate between individuals who do and do not experience SGs.
As hypothesized, a larger proportion of SGs predicted larger increases in BMI between baseline and 6, 12, and 24 months postrandomization. Importantly, there were no differences in BMI at baseline between those who did and did not experience SGs, suggesting that those experiencing SGs did not have a lower BMI at baseline and then regress towards the mean, as has been previously suggested (Konig, Karl, Rosner, & Butollo, 2014) . However, it may not be surprising that individuals who experienced more SGs in BMI during treatment had larger increases in BMI between baseline and follow-up, as SGs and outcomes were both measured from baseline, and therefore covered the same time period. Nevertheless, our results are clinically useful, as they provide insight into the process of change during the treatment of AN, and suggest that change in BMI during AN treatment often occurs suddenly between treatment sessions. Furthermore, our findings suggest that the SGs in BMI that are experienced during treatment are maintained at follow-up and are therefore preferable during treatment.
SGs most often occurred during the middle phases of treatment, a time when therapists typically work on eliciting change. This was especially true for MANTRA patients, suggesting that there may be something specific about these middle sessions, which elicit SGs. The focus on clinical formulation and the creation of treatment plans may be responsible for these SGs in BMI. These findings regarding the timings of SGs contradict some previous suggestions that SGs most often occur early during treatment. Within the present study, when defining SGs, there was no distinction made between those that occurred early and later during treatment, because of the considerable variation in the timing of SGs and the controversy regarding the definition of "early".
This variation in timing of SGs within the present sample may be because of the fact that, although treatments were manualized, there was considerable flexibility regarding the specific content of each therapy session. Thus, it is possible that certain topics covered during treatment coincided with SGs, but were covered in different sessions for different patients. Alternatively, it is possible that factors such as motivation to change, or therapeutic alliance were associated with SGs, rather than the content of treatment sessions.
In line with previous findings (Lutz et al., 2007) , amongst those experiencing at least one SG during treatment, fewer days between randomization and a patient's first SG predicted larger increases in BMI between baseline and both 6 and 12 months postrandomization. It may consequently be suggested that individuals who experience SGs earlier during treatment have better treatment outcomes. This association does not appear to be mediated by the total number of SGs experienced during treatment, as there was no significant correlation between proportion of SGs and the number of days between randomization and patients' first SG. Our findings did not support the hypothesis that the number of days between randomization and a patient's first SG would be predictive of BMI change between baseline and 24 months postrandomization.
| L I M I TA TI ONS AN D CON CL U S I ON
This study has several limitations. Firstly, almost 30% of MOSAIC patient files were missing. This was partly because of patients dropping out of the study prior to the start of treatment and therapist noncompliance with record keeping. However, it is also possible that files may have been missing for reasons, such as patients not attending therapy sessions. Similarly, there was a large variation in the number of weight measures recorded for each participant, and lack of consistency in the timing of these recordings, making it difficult to precisely investigate the trajectory of weight change. This complicated the calculations of SGs, requiring us to use the proportion of SGs rather than the raw number of SGs, making interpretation of these findings more challenging.
The MOSAIC study was not designed to investigate SGs and the data were therefore not optimal for the current study. Firstly, weight was the only variable to be measured at each session, limiting our choice as to how to define SGs. In addition, the number of days between weight measures varied considerably. Large gaps between measurements make it impossible to determine the true suddenness of SGs. Other possible reasons for missing weight data include the fact that there was a large variability in the number of treatment sessions attended by patients during the MOSAIC trial ;
and patients sometimes refused to be weighed. It is likely that this is not a random subsample of patients, further highlighting the challenges of missing data. We encourage future researchers to more rigorously collect session-by-session data for multiple variables in order to investigate SGs in BMI and other, psychological symptoms of AN.
Despite these limitations, the present study progresses research into the treatment of AN by suggesting that there are SGs in BMI during treatment, and that these are related to better long-term outcomes. Note. Unless otherwise stated, dependent variables were measured as the difference in symptoms between baseline and 24 months postrandomization. *p < .01, **p < .05.
Further research is, however, required to determine which components of therapy most often precede SGs in order to identify aspects of therapy that are most crucial in affecting change. Future research could also explore whether there are SGs in psychological symptoms of AN, and, if present, whether these are related to better outcomes. This would also allow comparisons to be made with research into SGs in CHEDS scores during treatment for bulimia nervosa (Cavallini & Spangler, 2013) .
In sum, the present study was the first to investigate SGs during the treatment of AN. Our findings provide support for previous research in other psychiatric disorders suggesting that SGs are associated with better treatment outcomes (Aderka et al., 2012) and suggest that patients show SGs in weight during treatment. Future research investigating factors that precede these SGs may help researchers to identify the components of therapy that are most important in affecting change in AN, and thereby contributing to the development of more effective treatments.
